|
1
|
Malpica A, Deavers MT, Lu K, et al:
Grading ovarian serous carcinoma using a two-tier system. Am J Surg
Pathol. 28:496–504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burks RT, Sherman ME and Kurman RJ:
Micropapillary serous carcinoma of the ovary. A distinctive
low–grade carcinoma related to serous borderline tumors. Am J Surg
Pathol. 20:1319–1330. 1996.
|
|
3
|
Lee Y, Miron A, Drapkin R, et al: A
candidate precursor to serous carcinoma that originates in the
distal fallopian tube. J Pathol. 211:26–35. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kindelberger DW, Lee Y, Miron A, et al:
Intraepithelial carcinoma of the fimbria and pelvic serous
carcinoma: Evidence for a causal relationship. Am J Surg Pathol.
31:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar
|
|
6
|
Malek A, Bakhidze E, Noske A, et al: HMGA2
gene is a promising target for ovarian cancer silencing therapy.
Int J Cancer. 123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park SM, Shell S, Radjabi AR, et al: Let-7
Prevents Early Cancer Progression by Suppressing Expression of the
Embryonic Gene HMGA2. Cell Cycle. 6:2585–2590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rzepka-Górska I, Chudecka-Glaz A and
Kosmowska B: FSH and LH serum/tumor fluid ratios and malignant
tumors of the ovary. Endocr Relat Cancer. 11:315–321.
2004.PubMed/NCBI
|
|
9
|
Ohtani K, Sakamoto H, Kikuchi A, et al:
Follicle-stimulating hormone promotes the growth of human
epithelial ovarian cancer cells through the protein kinase
C-mediated system. Cancer Lett. 166:207–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji Q, Liu PI, Chen PK, et al: Follicle
stimulating hormone-induced growth promotion and gene expression
profiles on ovarian surface epithelial cells. Int J Cancer.
112:803–814. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Levanon K, Ng V, Piao HY, et al: Primary
ex vivo cultures of human fallopian tube epithelium as a model for
serous ovarian carcinogenesis. Oncogene. 29:1103–1113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fotheringham S, Levanon K and Drapkin R:
Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells. J
Vis Exp. pii. 27282011.PubMed/NCBI
|
|
13
|
Brekelmans CT: Risk factors and risk
reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol.
15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang Y, Hua K, Zhou X, et al: Activation
of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in
ovarian serous cystadenocarcinoma. Cell Res. 18:780–791. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng W, Magid MS, Kramer EE and Chen YT:
Follicle-stimulating hormone receptor is expressed in human ovarian
surface epithelium and fallopian tube. Am J Pathol. 148:47–53.
1996.PubMed/NCBI
|
|
16
|
Wei JJ, Wu J, Luan C, et al: HMGA2: a
potential biomarker complement to P53 for detection of early-stage
high-grade papillary serous carcinoma in fallopian tubes. Am J Surg
Pathol. 34:18–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Levanon K, Crum C and Drapkin R: New
insights into the pathogenesis of serous ovarian cancer and its
clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson SM, Grosshans H, Shingara J, et
al: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumar MS, Lu J, Mercer KL, et al: Impaired
microRNA processing enhances cellular transformation and
tumorigenesis. Nat Genet. 39:673–677. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shell S, Park SM, Radjabi AR, et al: Let-7
expression defines two differentiation stages of cancer. Proc Natl
Acad Sci USA. 104:11400–11405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mayr C, Hemann MT and Bartel DP:
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic
transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hebert C, Norris K, Scheper MA, et al:
High mobility group A2 is a target for miRNA-98 in head and neck
squamous cell carcinoma. Mol Cancer. 6:52007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahajan A, Liu Z, Gellert L, et al: HMGA2:
A biomarker significantly overexpressed in high-grade ovarian
serous carcinoma. Modern Pathology. 23:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
